Recurrent de novo missense variants in GNB2 can cause syndromic intellectual disability

Purpose Binding proteins (G-proteins) mediate signalling pathways involved in diverse cellular functions and comprise Gα and Gβγ units. Human diseases have been reported for all five Gβ proteins. A de novo missense variant in GNB2 was recently reported in one individual with developmental delay/intellectual disability (DD/ID) and dysmorphism. We aim to confirm GNB2 as a neurodevelopmental disease gene, and elucidate the GNB2-associated neurodevelopmental phenotype in a patient cohort. Methods We discovered a GNB2 variant in the index case via exome sequencing and sought individuals with GNB2 variants via international data-sharing initiatives. In silico modelling of the variants was assessed, along with multiple lines of evidence in keeping with American College of Medical Genetics and Genomics guidelines for interpretation of sequence variants. Results We identified 12 unrelated individuals with five de novo missense variants in GNB2, four of which are recurrent: p.(Ala73Thr), p.(Gly77Arg), p.(Lys89Glu) and p.(Lys89Thr). All individuals have DD/ID with variable dysmorphism and extraneurologic features. The variants are located at the universally conserved shared interface with the Gα subunit, which modelling suggests weaken this interaction. Conclusion Missense variants in GNB2 cause a congenital neurodevelopmental disorder with variable syndromic features, broadening the spectrum of multisystem phenotypes associated with variants in genes encoding G-proteins.

[1]  G. Merla,et al.  The Emerging Role of Gβ Subunits in Human Genetic Diseases , 2019, Cells.

[2]  T. Ogata,et al.  Exome reports A de novo GNB2 variant associated with global developmental delay, intellectual disability, and dysmorphic features. , 2019, European journal of medical genetics.

[3]  D. Goldstein,et al.  Refining the phenotype associated with GNB1 mutations: Clinical data on 18 newly identified patients and review of the literature , 2018, American journal of medical genetics. Part A.

[4]  R. Płoski,et al.  Novel GNB1 de novo mutation in a patient with neurodevelopmental disorder and cutaneous mastocytosis: Clinical report and literature review. , 2017, European journal of medical genetics.

[5]  Xiaojuan Zhu,et al.  G&bgr;2 Regulates the Multipolar-Bipolar Transition of Newborn Neurons in the Developing Neocortex , 2017, Cerebral cortex.

[6]  E. Schulze-Bahr,et al.  A Mutation in the G-Protein Gene GNB2 Causes Familial Sinus Node and Atrioventricular Conduction Dysfunction , 2017, Circulation research.

[7]  R. Dey,et al.  Regulation, Signaling, and Physiological Functions of G-Proteins. , 2016, Journal of molecular biology.

[8]  J. Rosenfeld,et al.  Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. , 2016, American journal of human genetics.

[9]  S. Sprang Invited review: Activation of G proteins by GTP and the mechanism of Gα‐catalyzed GTP hydrolysis , 2016, Biopolymers.

[10]  Orion J. Buske,et al.  The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery , 2015, Human mutation.

[11]  B. Ebert,et al.  Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance , 2014, Nature Medicine.

[12]  D. Siderovski,et al.  Regulators of G-Protein Signaling and Their Gα Substrates: Promises and Challenges in Their Use as Drug Discovery Targets , 2011, Pharmacological Reviews.

[13]  H. Hamm,et al.  Heterotrimeric G protein activation by G-protein-coupled receptors , 2008, Nature Reviews Molecular Cell Biology.

[14]  K. Yan,et al.  The G-protein betagamma complex. , 1998, Cellular signalling.

[15]  L. Jan,et al.  Molecular basis for interactions of G protein betagamma subunits with effectors. , 1998, Science.